350 related articles for article (PubMed ID: 10379632)
1. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
3. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
Hägg S; Spigset O; Dahlqvist R
Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
[TBL] [Abstract][Full Text] [Related]
6. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
7. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
8. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
9. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
Kuhlmann JB; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
[TBL] [Abstract][Full Text] [Related]
11. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
12. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
Laine K; Tybring G; Bertilsson L
Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
[TBL] [Abstract][Full Text] [Related]
13. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
14. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
15. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
16. The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
Baumann P; Eap CB; Gastpar M
Basic Clin Pharmacol Toxicol; 2020 May; 126(5):444-447. PubMed ID: 31814297
[TBL] [Abstract][Full Text] [Related]
17. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
[TBL] [Abstract][Full Text] [Related]
18. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
20. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
